New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
05:01 EDTDVAX, BRCM, BA, CLNE, DKS, SODA, EXEL, CSCO, WPRT, GILD, HD, SAND, O, QCOM, GE, CELGJim Cramer's "Mad Money"
Jim Cramer said there are plenty of reasons to still own stocks. As many are still hopeful for a deal that can avert the fiscal cliff. So why haven't stock prices cratered in the meantime? Cramer said there are many reasons. Many investors simply aren't aware of drastic consequences if a deal is not reached, while others have their investments in IRAs and other tax-favored accounts that may not be affected by the fiscal cliff. Those investors are buyers into weakness and help provide a cushion for the markets, Cramer said. Then there are the earnings, strong earnings, from the likes of Home Depot (HD) and Dicks Sporting Goods (DKS), which prove that Americans are still spending, especially on their homes. Other big moves, including from biotechs like Celgene (CELG) and Gilead Sciences (GILD), are hard to pass up, Cramer continued. In the end, being out of the market when a deal is reached would be a huge mistake, Cramer said, as even a bad outcome is better than no outcome at all. EXECUTIVE DECISION: Cramer once again sat down with Andrew Littlefair, CEO of Clean Energy Fuels (CLNE), a stock that's been cut in half since its highs earlier this year, but also one that received a boost Tuesday on the news that the company is building two liquefied natural gas plants with General Electric (GE). Littlefair said ultimately, Clean Energy plans 10 such plants, allowing the company to provide fuel along the major interstate corridors across our country. When Westport Innovations (WPRT) introduces the next-generation natural gas engines in February, Littlefair added, that will likely be the catalyst to convince many more truckers to begin using natural gas and start saving up to $1.50 per gallon in fuel costs. Cramer said Littlefair made him feel more upbeat on the prospects for natural gas in America. OFF THE CHARTS: Cramer and colleague Bob Lang went over the chart of Boeing (BA), one that is squarely in the crosshairs of the looming fiscal cliff. With a floor at $69 a share, Lang said investors have decent downside protection at these levels. More importantly, Boeing's recent rally now puts the stock above its 10-day, 50-day and 200-day moving averages, which makes it an "up stock" in the eyes of technicians who follow it. Cramer said there's a tremendous buying cycle at hand in the aerospace world, as more and more airlines need to add more fuel efficient planes to their fleets. This cycle lasts for years, he said, which is why Boeing is one stock that can fly higher than even the fiscal cliff. NO HUDDLE OFFENSE: Cramer took a moment out to praise the management at Home Depot and Dicks Sporting Goods for their remarkable earnings.Home Depot. LIGHTNING ROUND: (Bullish) QCOM; CSCO; BRCM; O; EXEL; DVAX. (Bearish) SAND; SODA.is now set to ride the waves of a recovering housing market and the rebuilding effort after Hurricane Sandy. Cramer said Dick's 5% pop in same store sales was remarkable during a time when many are not necessarily in the market for expensive sneakers or outdoor sporting gear. Reference Link
News For HD;DKS;CELG;GILD;CLNE;GE;WPRT;BA;QCOM;CSCO;BRCM;O;EXEL;DVAX;SAND;SODA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
December 8, 2014
15:18 EDTBRCMBroadcom December volatility elevated into analyst day
Broadcom December weekly call option implied volatility is at 53, December is at 34, January is at 27; compared to its 26-week average of 26 according to Track Data, suggesting large near term price movement into a company sponsored analyst day on December 10.
14:06 EDTCELGCelgene reports luspatercept, sotatercept increased hemoglobin levels in trials
Subscribe for More Information
13:54 EDTCELGCelgene announces results from phase lll Revlimid study
Subscribe for More Information
12:40 EDTCSCOUS Supreme Court to hear appeal in patent fight with Cisco
The U.S. Supreme Court has agreed to hear an appeal of a controversial appeals court decision that set aside a $63.8M patent infringement verdict won by The Woodlands, Texas-based Commil USA LLC against Cisco
10:02 EDTGILDGilead presents follow-up data from Zydelig registrational studies
Subscribe for More Information
10:00 EDTCLNEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:40 EDTCSCODeutsche Bank and Cisco to host a conference call
Subscribe for More Information
08:02 EDTCSCOAruba says NHS replaces Cisco network with Aruba wireless infrastructure
Subscribe for More Information
07:49 EDTCSCOArista Networks lawsuit not as threatening as believed, says SunTrust
Subscribe for More Information
07:36 EDTCELGAgios announces Celgene to extend discovery phase of collaboration to April 2016
Agios Pharmaceuticals (AGIO) announced that Celgene (CELG) has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The terms of the collaboration extension are consistent with previously agreed upon financial terms. As a result of the extension, Celgene will maintain its exclusive option to drug candidates that emerge from Agios' cancer metabolism research platform through April 2016. Agios will receive a $20M payment. Following this extension, the discovery portion of the collaboration will expire on April 14, 2016. Under the terms of the original agreement announced in April 2010, Agios leads research, preclinical and early development efforts through Phase 1, while Celgene receives an option to obtain exclusive rights either upon IND acceptance or at the end of Phase 1, to further development and commercialize medicines emerging from Agios' cancer metabolism research. Celgene would lead and fund global development and commercialization of some of these drugs, and Agios would retain development and commercialization rights for certain drugs in the United States. On all programs, Agios is eligible to receive up to $120M in milestone-based payments as well as royalties on any sales.
07:32 EDTCSCORaymond James to hold a conference
Subscribe for More Information
07:31 EDTQCOMQualcomm announces collabration with vitaphone e-health solutions
Subscribe for More Information
07:17 EDTCELGCelgene price target raised to $131 from $120 at Cantor
Subscribe for More Information
07:03 EDTCSCOArista Networks patent resolution likely 2-3 years away, says Citigroup
Subscribe for More Information
05:43 EDTBABoeing Business Jets, Comlux announces order for two BBJ MAX 8s
Subscribe for More Information
05:42 EDTCLNEClean Energy downgraded to Hold from Buy at Ascendiant
Subscribe for More Information
05:35 EDTCELGCelgene REVLIMID, low-dose dexamethasone increased PFS
Subscribe for More Information
December 7, 2014
16:40 EDTCELGAgios announces new data from Ongoing Phase 1 trial of AG-221
Subscribe for More Information
14:10 EDTCELGAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:16 EDTCELGCelgene, Acceleron announced data from luspatercept phase 2 clinical trial
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use